Experts Lead Discussion on COVID-19 Impact on RWD and Potential Uses of RWE

The Evidence Base hosted three real world evidence (RWE) experts from Pfizer, Syapse, and the Santa Chiara Hospital in Italy. They discussed topics ranging from RWE applications to improving real world data (RWD) methods to the impact of the COVID-19 pandemic on RWD sources.

Syapse’s Dr. Thomas Brown notes, “A growing number of collaborations, involving a range of stakeholders including the FDA, are underway with the goal of standardizing the use of real-world evidence. My hope is that these collaborations further establish standards of quality to include further validation of outcome endpoints most appropriate for real-world data,” adding, “I believe that real-world evidence can be routinized for regulatory filings, creating clearer paths for leveraging real-world evidence in New Drug Applications. I also hope that we will soon leave behind the notion that real-world evidence and classical prospective clinical trials are in perpetual competition, and begin to recognize the important nexus of the two.” Read more here.

(Source: The Evidence Base, 5/19/21)